Evidence map›Paper›PMID 41256256›Full record

ArticleFrontiers in pharmacology2025

Characterization of

Reda Chahir, Jacob Galan, Hicham Hboub, Ahmed Salim Lahlou, Salma Chakir, Hinde Aassila, Reda Ben Mrid, Najat Bouchmaa, Reto Stöcklin, Rachid El Fatimy and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Reda ChahirLaboratory of Venoms and Toxins, Pasteur Institute of Morocco, Casablanca, Morocco.
Jacob GalanDepartment of Human Genetics, The University of Texas Rio Grande Valley School of Medicine, Brownsville, TX, United States.
Hicham HboubFaculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir, Morocco.
Ahmed Salim LahlouLaboratory of Venoms and Toxins, Pasteur Institute of Morocco, Casablanca, Morocco.
Salma ChakirLaboratory of Venoms and Toxins, Pasteur Institute of Morocco, Casablanca, Morocco.
Hinde AassilaFaculty of Science and Technology, Agri-Food and Health Laboratory, Hassan First University of Settat, Settat, Morocco.
Reda Ben MridFaculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir, Morocco.
Najat BouchmaaFaculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir, Morocco.
Reto StöcklinAtheris Laboratories, Geneva, Switzerland.
Rachid El FatimyFaculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir, Morocco.
Naoual OukkacheLaboratory of Venoms and Toxins, Pasteur Institute of Morocco, Casablanca, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal venom, known for its complex biochemical composition, presents a valuable source of therapeutic molecules, particularly for antiviral applications. Despite this potential, the industrial use of venom remains limited, with fewer than a dozen venom-derived compounds reaching commercial markets. This study underscores the significance of exploring venom's natural diversity as a reservoir for novel bioactive compounds that could drive innovative drug development. We investigated the venom of the Moroccan black scorpion

Indexed as

Androctonus mauritanicusantiviral peptidesmass spectrometryproteomicsSARS-CoV-2scorpion venom

Identifiers

PMID41256256
PMCPMC12620373

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.